8-K: Oncotelic Secures $398K Debt, Warrants from Mast Hill Fund

Oncotelic Therapeutics, Inc. has entered into a securities purchase agreement with Mast Hill Fund, L.P., securing a $398,333.33 senior secured convertible promissory note and issuing warrants and commitment shares.

Summary

• Oncotelic Therapeutics, Inc. (OTLC) entered into a Securities Purchase Agreement with Mast Hill Fund, L.P. on January 23, 2026.
• The agreement includes a senior secured convertible promissory note with a principal amount of $398,333.33, purchased for $358,500.00, reflecting an original issue discount (OID) of $39,833.33.
• The note carries an interest rate of 10% per annum and matures on the earlier of its one-year anniversary (January 23, 2027), acceleration upon an Event of Default, or full prepayment.
• The note is convertible into common stock at a fixed price of $0.07 per share, subject to adjustments.
• The company also issued 1,422,613 warrants to purchase common stock at an exercise price of $0.15 per share, exercisable for five years from the issuance date.
• Additionally, 1,600,446 commitment shares of common stock were issued to Mast Hill Fund, L.P. as additional consideration.
• The note is secured against substantially all of the company's assets, including OT-101, CA4P, Oxi4503, AI and AI CDMO technologies, and the nanoparticle platform, but excludes assets within its joint venture with Dragon Overseas Capital Limited (GMP Biotechnology and its subsidiaries).
• Proceeds from the transaction are designated for general working capital and are restricted from certain uses, such as repayment of affiliate indebtedness or loans to officers/directors.
• The company must maintain a reserve of common stock for conversions and exercises, specifically the greater of 32,000,000 shares or four times the number of shares issuable upon full conversion of the note, and four times the number of shares issuable upon full exercise of the warrants.
• Various events of default are defined, including failure to pay, failure to issue conversion shares, breach of covenants, market capitalization falling below $5,000,000, and delisting/suspension of trading.
• Upon an Event of Default, the outstanding principal and accrued interest become immediately due and payable at 150% of the amount, plus collection costs, or the holder may convert at the lesser of the then-applicable conversion price or the market price.
• The company is prohibited from entering into Variable Rate Transactions or Prohibited Transactions (e.g., merchant cash advances, sale of receivables) and from issuing other equity or debt securities for 180 days without the holder's consent.
• The company must grant the holder 'most favored nation' status for any more favorable terms offered to other investors in future financings.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly dilutive and costly financing for Oncotelic, indicative of a challenging capital environment for the company, despite providing immediate liquidity.

Positives

• The company secured $358,500.00 in capital, providing funds for general working capital and business development.
• The financing is secured, potentially offering stability to the lender and indicating some asset backing for the debt.

Negatives

• The note includes a significant Original Issue Discount (OID) of $39,833.33, meaning the company received less cash than the principal amount it owes.
• The interest rate of 10% per annum is relatively high, increasing the cost of capital for the company.
• A default interest rate of 18% per annum (or maximum legal rate) applies if payments are not made when due, significantly increasing the cost of default.
• The issuance of 1,422,613 warrants and 1,600,446 commitment shares, along with the convertible nature of the note, presents substantial potential for dilution to existing shareholders.
• The conversion price of $0.07 per share for the note is significantly lower than the warrant exercise price of $0.15, indicating a potentially aggressive valuation for the conversion feature.
• The company faces numerous stringent covenants and events of default, including maintaining a minimum market capitalization of $5,000,000 and strict adherence to share issuance and reporting requirements, with severe penalties (150% of principal plus interest upon default).
• The 'Repayment from Proceeds' clause allows the holder to demand repayment of up to 30% of any cash proceeds received by the company, which could limit the company's financial flexibility for other strategic initiatives.
• The prohibition on 'Variable Rate Transactions' and 'Prohibited Transactions' for the life of the note restricts future financing options for the company.

Risks

• Significant shareholder dilution from the conversion of the note and exercise of warrants, as well as the issuance of commitment shares.
• High cost of capital due to the 10% interest rate and the 10% OID.
• Exposure to substantial penalties (150% of outstanding principal and interest) upon an Event of Default, which could severely impact financial stability.
• Operational and financial flexibility is constrained by numerous covenants, including restrictions on incurring additional senior or pari passu indebtedness, making certain distributions, repurchasing stock, or selling significant assets outside the ordinary course of business without the holder's consent.
• Risk of triggering an Event of Default if market capitalization falls below $5,000,000, leading to immediate acceleration of the debt at a premium.
• Inability to obtain a Rule 144 legal opinion after six months or issues with the transfer agent could trigger an Event of Default, hindering the holder's ability to sell shares and potentially leading to penalties for the company.
• The company is prohibited from entering into certain types of financing (Variable Rate Transactions, Prohibited Transactions) and from issuing other equity or debt securities for 180 days, limiting its ability to raise additional capital quickly if needed.
• The 'most favored nation' clause means any more favorable terms offered to future investors would automatically apply to this holder, potentially increasing the company's obligations to Mast Hill Fund, L.P.

Future Outlook

The filing indicates the company intends to use the capital for general working capital and business development. However, the stringent covenants and potential for significant dilution and penalties upon default suggest a cautious outlook regarding the company's financial flexibility and future equity structure.

Management Comments

• Vuong Trieu, Chief Executive Officer, signed the agreements on behalf of Oncotelic Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that securing a senior secured convertible note with a significant OID and high interest rate, coupled with substantial warrant and commitment share issuances, is often indicative of a company facing challenges in accessing more traditional or less dilutive forms of financing. For a biotechnology company like Oncotelic, which relies heavily on capital for R&D and clinical trials (implied by assets like OT-101, CA4P, Oxi4503, AI, and nanoparticle platform), such financing can be a necessary but costly means to sustain operations. The strict covenants and numerous events of default suggest a lender-favorable agreement, common in situations where the borrower's risk profile is elevated.

Comparison to Industry Standards

• The 10% annual interest rate and 10% OID are higher than typical rates for established biotech companies, reflecting a higher perceived risk by the lender. For example, larger, more stable biotech firms might secure debt at 5-7% with minimal or no OID.
• The conversion price of $0.07, significantly below the warrant exercise price of $0.15, suggests a valuation that heavily favors the investor's ability to convert debt into equity at a low price, potentially indicating a distressed financing scenario compared to growth-stage biotech companies that often negotiate higher conversion premiums.
• The 4.99% beneficial ownership limitation is a standard provision to avoid triggering Schedule 13D filing requirements for the investor, common in such private placements.
• The extensive list of Events of Default, including a $5,000,000 market capitalization threshold and penalties for Rule 144 non-compliance, is more typical of highly structured, high-risk debt financing compared to standard corporate loans or venture debt for healthier companies.
• The 'most favored nation' clause and restrictions on future financings (e.g., Variable Rate Transactions, 180-day lock-up on new equity/debt) are common in investor-friendly debt agreements designed to protect the initial investor's position against subsequent dilutive or unfavorable deals, but they can severely limit the company's future capital-raising flexibility compared to peers with more open financing options.

Corporate Governance

Related Party Transactions

• The use of proceeds is restricted from the repayment of any indebtedness owed to officers, directors, or employees of the Company or their affiliates, and from any loan, credit, or advance to any officers, directors, employees, or affiliates of the Company.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of the note, exercise of warrants, and issuance of commitment shares. The low conversion price and high default penalties could further erode shareholder value.
• **Creditors (other than Mast Hill Fund)**: The senior secured nature of the note means Mast Hill Fund, L.P. has priority over other unsecured creditors in case of default or liquidation, potentially reducing recovery for other creditors.
• **Employees/Management**: The stringent covenants and potential for Events of Default could create pressure on management to meet financial and operational targets, and restrictions on affiliate transactions limit certain compensation or loan opportunities.
• **Company Operations**: The capital infusion provides immediate working capital for business development, but the restrictive covenants and potential for forced repayment from future proceeds could limit strategic flexibility and long-term growth initiatives.

Next Steps

• The company must file an initial Registration Statement covering the maximum number of Registrable Securities within 60 calendar days from January 23, 2026.
• The company must ensure the Registration Statement is declared effective by the SEC within 120 calendar days from January 23, 2026.
• The company must maintain the listing and trading of its Common Stock on the Principal Market.
• The company must purchase director and officer insurance within 60 calendar days of the closing, providing 18 months of coverage with two years of tail coverage.

Key Dates

Recommendation

The terms of this financing are highly unfavorable for Oncotelic Therapeutics, Inc. The significant Original Issue Discount, high interest rates, and substantial potential for dilution from the convertible note, warrants, and commitment shares will severely pressure the company's equity value. The numerous and stringent Events of Default, including a low market capitalization threshold and severe penalties (150% of principal upon default), expose the company to substantial financial risk and limit its operational and financial flexibility. The restrictions on future financings and the 'most favored nation' clause further constrain the company's ability to raise capital on better terms. These factors collectively indicate a precarious financial position and a high likelihood of further value erosion for existing shareholders.

Keywords

Convertible Note, Warrants, Secured Debt, Dilution, Capital Raise, SEC Filing, Oncotelic Therapeutics, Mast Hill Fund, Corporate Finance, OTLC